Quick Answer
Adaptive Biotechnologies Corp reported Cash and Equivalents of $70.50 million for fiscal year 2025.
Adaptive Biotechnologies Corp Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $70.50M | +47.1% |
| 2024 | $47.92M | -26.3% |
| 2023 | $65.06M | -27.7% |
| 2022 | $90.03M | -35.3% |
| 2021 | $139.06M | +12.7% |
| 2020 | $123.44M | +27.8% |
| 2019 | $96.58M | +75.5% |
| 2018 | $55.03M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $55.03M | +44.5% | +27.5% |
| June 30, 2025 | $43.16M | -27.9% | -14.8% |
| March 31, 2025 | $50.65M | -28.9% | +5.7% |
| December 31, 2024 | $47.92M | -26.3% | +25.8% |
| September 30, 2024 | $38.08M | -57.1% | -36.3% |
| June 30, 2024 | $59.82M | -45.2% | -16.0% |
| March 31, 2024 | $71.23M | -24.7% | +9.5% |
| December 31, 2023 | $65.06M | -27.7% | -26.7% |
- Adaptive Biotechnologies Corp showed an increase of +47.1% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2018–2025 period, Adaptive Biotechnologies Corp’s cash and equivalents has grown by 28.1% (from $55.03 million to $70.50 million).
- The most recent figure is from Adaptive Biotechnologies Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: